Budesonide inhalation suspension - AstraZeneca

Drug Profile

Budesonide inhalation suspension - AstraZeneca

Alternative Names: Pulmicort Respules; S1320 inhalation suspension - AstraZeneca

Latest Information Update: 17 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma
  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 17 Feb 2015 The United States District Court for the District of New Jersey invalidates the US Patent No. 7 524 834
  • 01 Aug 2012 Generic equivalent from Actavis approved in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top